Mirum Pharmaceuticals (MEX:MIRM) LT-Debt-to-Total-Asset : 0.47 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mirum Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Mirum Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.47.

Mirum Pharmaceuticals's long-term debt to total assets ratio increased from Mar. 2023 (0.00) to Mar. 2024 (0.47). It may suggest that Mirum Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Mirum Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Mirum Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals LT-Debt-to-Total-Asset Chart

Mirum Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

0.48

Mirum Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	0.69	0.47	0.48	0.47

Mirum Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Mirum Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	5211.739	/	10975.905
	=	0.47

Mirum Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	5097.755	/	10820.128
	=	0.47

Mirum Pharmaceuticals (MEX:MIRM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Mirum Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirum Pharmaceuticals (MEX:MIRM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (MEX:MIRM) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

MIRM:USA 08D:Germany

Address

950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404

Website

https://www.mirumpharma.com

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.